IGF1R and sarcoma: Early phase clinical trials encouraged the benefit of IGF1R inhibition against sarcomas, however, as predicted, resistance to the IGF1R inhibitors developed in most cases which initially responded to the therapy, and eventually suffered from relapses 24.